Lv1
28 积分 2024-02-22 加入
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
3天前
已完结
Lessons from incretin-based therapy in MASH and obesity
10天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
10天前
已完结
Resmetirom for MASH-related cirrhosis
10天前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
10天前
已完结
Envisioning how to advance the MASH field
11天前
已完结
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
11天前
已完结
A roadmap for clinical trials in MASH-related compensated cirrhosis
11天前
已完结
Fibroblast lipid metabolism through ACSL4 regulates epithelial sensitivity to ferroptosis in IBD
17天前
已完结
Dietary control of peripheral adipose storage capacity through membrane lipid remodelling
18天前
已完结
皖公网安备34019202002308
